Zwart Ruud, Peeva Polina M, Rong James X, Sher Emanuele
Neuroscience Discovery Research, Lilly Research Centre, Eli Lilly and Company, Windlesham, United Kingdom (R.Z., P.M.P., E.S.); and Lilly China Research and Development Center, Eli Lilly and Company, Shanghai, China (J.X.R.)
Neuroscience Discovery Research, Lilly Research Centre, Eli Lilly and Company, Windlesham, United Kingdom (R.Z., P.M.P., E.S.); and Lilly China Research and Development Center, Eli Lilly and Company, Shanghai, China (J.X.R.).
J Pharmacol Exp Ther. 2015 Nov;355(2):247-54. doi: 10.1124/jpet.115.226902. Epub 2015 Aug 31.
The citric acid cycle intermediate citrate plays a crucial role in metabolic processes such as fatty acid synthesis, glucose metabolism, and β-oxidation. Citrate is imported from the circulation across the plasma membrane into liver cells mainly by the sodium-dependent citrate transporter (NaCT; SLC13A5). Deletion of NaCT from mice led to metabolic changes similar to caloric restriction; therefore, NaCT has been proposed as an attractive therapeutic target for the treatment of obesity and type 2 diabetes. In this study, we expressed mouse and human NaCT into Xenopus oocytes and examined some basic functional properties of those transporters. Interestingly, striking differences were found between mouse and human NaCT with respect to their sensitivities to citric acid cycle intermediates as substrates for these transporters. Mouse NaCT had at least 20- to 800-fold higher affinity for these intermediates than human NaCT. Mouse NaCT is fully active at physiologic plasma levels of citrate, but its human counterpart is not. Replacement of extracellular sodium by other monovalent cations revealed that human NaCT was markedly less dependent on extracellular sodium than mouse NaCT. The low sensitivity of human NaCT for citrate raises questions about the translatability of this target from the mouse to the human situation and raises doubts about the validity of this transporter as a therapeutic target for the treatment of metabolic diseases in humans.
柠檬酸循环中间体柠檬酸在脂肪酸合成、葡萄糖代谢和β氧化等代谢过程中起着关键作用。柠檬酸主要通过钠依赖性柠檬酸转运体(NaCT;SLC13A5)从循环中穿过质膜进入肝细胞。从小鼠中删除NaCT会导致类似于热量限制的代谢变化;因此,NaCT已被提议作为治疗肥胖症和2型糖尿病的一个有吸引力的治疗靶点。在本研究中,我们将小鼠和人类的NaCT表达于非洲爪蟾卵母细胞中,并检测了这些转运体的一些基本功能特性。有趣的是,在小鼠和人类NaCT对作为这些转运体底物的柠檬酸循环中间体的敏感性方面发现了显著差异。小鼠NaCT对这些中间体的亲和力比人类NaCT至少高20至800倍。小鼠NaCT在生理血浆柠檬酸水平时具有完全活性,但其人类对应物则不然。用其他单价阳离子替代细胞外钠表明,人类NaCT对细胞外钠的依赖性明显低于小鼠NaCT。人类NaCT对柠檬酸的低敏感性引发了关于该靶点从小鼠向人类情况转化的可翻译性的问题,并对该转运体作为人类代谢疾病治疗靶点的有效性产生了怀疑。